Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHYP | ISIN: US89422G1076 | Ticker-Symbol: 17R
Berlin
31.03.25
08:15 Uhr
18,100 Euro
-0,100
-0,55 %
1-Jahres-Chart
TRAVERE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TRAVERE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
17,90018,40009:02

Aktuelle News zur TRAVERE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIBD Stock Of The Day Travere Therapeutics: A Breakout And $1 Billion Opportunity Loom1
17.03.Travere Therapeutics, Inc. - 8-K, Current Report-
17.03.Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS125sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney...
► Artikel lesen
TRAVERE THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Travere Therapeutics (NASDAQ:TVTX) Trading Up 6.7% - Time to Buy?1
12.03.Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)68SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement...
► Artikel lesen
24.02.Analyst Expectations For Travere Therapeutics' Future5
23.02.Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 20251
21.02.Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Estimates By $0.15 EPS1
21.02.After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder1
21.02.Travere Therapeutics, Inc. - 10-K, Annual Report-
20.02.Travere Therapeutics, Inc.: Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results122Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full...
► Artikel lesen
20.02.Travere Therapeutics, Inc. - 8-K, Current Report1
13.02.Travere Therapeutics, Inc.: Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results2
12.02.Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)65SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement...
► Artikel lesen
12.02.Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday?1
12.02.Scotiabank raises Travere stock target to $32 on FDA update5
12.02.Canaccord raises Travere Therapeutics target to $45; Keeps Buy1
12.02.Travere takes rare disease kidney drug to FDA despite failed trial2
11.02.Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug3
11.02.Travere Therapeutics stock soars on FDA meeting outcome3
Seite:  Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1